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Purpose: To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction
following intravitreal delivery of adeno-associated virus-2 (AAV2).
Methods: AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken
β-actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase,
hyaluronan lyase, heparinase III, or chondroitin ABC lyase. Two weeks later, retinal flatmounts were examined for GFP
expression using confocal microscopy.
Results: Without the addition of enzymes, transduction was limited to occasional cells in the retinal ganglion cell layer.
The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer
and increased the depth of transduction into the outer retina. Hyaluronan lyase had a limited effect and collagenase was
ineffective. Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than
were required for optimal retinal transduction.
Conclusions: AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC
lyase. Improved transduction efficiency may allow intravitreal injection to become the preferred route for delivering gene
therapy to both the inner and outer retina.
To date, adeno-associated virus (AAV) has been the most
effective vector for retinal gene delivery because it elicits
minimal  immune  response  and  can  mediate  long-term
transgene expression in a variety of non-dividing retinal cell
types. AAV is a nonhuman pathogen of the Parvoviridae
family possessing a single-stranded DNA genome (4.7 kb)
with two open reading frames, rep (for replication) and cap
(encodes capsid proteins), flanked by two symmetric inverted
terminal repeats. Recombinant AAV vectors are generated by
replacing rep and cap with the required cDNA [1].
The prototype and the most studied AAV is serotype-2
(AAV2).  This  has  been  used  in  clinical  trials,  with  very
encouraging results, to treat Leber congenital amaurosis by
transducing the retinal pigment epithelium with RPE65 cDNA
[2-4]. In addition, a variety of other AAV serotypes and hybrid
forms have been shown to be capable of retinal transduction
[1,5]. In most studies to date, subretinal injection has been
used to deliver AAV to the retina.
This delivery method creates a temporary separation bleb
between  the  neurosensory  retina  and  the  retinal  pigment
epithelium,  providing  gene  delivery  to  neighboring  cells.
Intravitreal  delivery  has  potential  advantages  over  this
subretinal approach because it is less technically challenging
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and  is  less  prone  to  complications,  particularly  through
surgical manipulation of thin degenerating retinas, which may
cause retinal hemorrhage, tear or detachment. Furthermore,
the  intravitreal  approach  can  potentially  deliver  more
widespread transduction across the retina when compared to
localized subretinal blebs.
Intravitreal injection has been used to transduce retinal
ganglion cells and bipolar cells, but at present this approach
produces relatively low efficiency retinal transduction. One
potential limit to the efficacy of intravitreal viral injection
stems  from  the  physical  barriers  formed  by  the  vitreous,
internal limiting membrane (ILM), retinal extracellular matrix
(ECM), and cell surface proteoglycans. The vitreous, ILM,
and retinal ECM all contain glycosaminoglycans (GAGs),
while the vitreous and ILM contain collagens. The vitreous is
a  highly  hydrated  ECM  that  contains  GAGs  and  a  low
concentration of collagen fibrils [6]. The predominant GAG
in vitreous is hyaluronan (HA), but it also contains small
amounts of chondroitin sulfate proteoglycans (CSPGs). The
ILM  contains  a  basement  membrane  called  the  internal
limiting lamina (ILL); this is a sheet-like extracellular matrix
containing type IV collagen, laminins, nidogen-1 and 2, and
heparan  sulfate  proteoglycans  (HSPGs)  that  include  type
XVIII collagen, perlecan, and agrin [7]. The neurosensory
retina contains chondroitin and heparan sulfate proteoglycans,
but a mouse retina does not contain HA [8,9]. Cell surface
heparan  sulfate  proteoglycans  are  present  in  the  retina,
particularly on the neurites of neuronal cells. Chondroitin
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1771sulfate proteoglycans are present in the ILM, in the nerve
fiber-rich layers of the retina, which include the inner and
outer plexiform layer, and in the interphotoreceptor matrix
(IPM) [8].
We hypothesized that enzymatic degradation of collagen
or  specific  GAGs  would  increase  retinal  transduction
efficiency with AAV2. We therefore tested the efficacy of co-
injecting extracellular matrix degrading enzymes with AAV2
into the mouse vitreous on retinal expression of a reporter gene
(enhanced green fluorescent protein; GFP) contained within
the  viral  vector.  We  found  that  both  heparinase  III  and
chondroitin ABC lyase markedly improved the efficiency of
retinal transduction.
METHODS
Experimental  animals:  All  animal  experiments  were
conducted  in  accordance  with  the  UK  Home  Office
regulations for the care and use of laboratory animals, the UK
Animals (Scientific Procedures) Act (1986), and the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. Adult Opn4-/+ and wild-type C57BL/6J mice were
used for all studies. All mice were kept under a 12 h:12 h light-
dark cycle and were given free access to food and water.
Generation of rAAV vectors: The vector, rAAV serotype 2
(rAVETM), expressing GFP under the control of a chicken
β-actin  promoter  (AAV-2.CBA.eGFP)  was  obtained  from
Genedetect, Auckland, New Zealand.
Enzymes and dilutions: The following enzymes, all obtained
from Sigma-Aldrich (Dorset, UK), were used: high purity
bacterial collagenase (from Clostridium histolyticum, Type
VII);  hyaluronan  lyase  from  Streptomyces  (E.C.  4.2.2.1),
which has a high specificity for hyaluronan; Chondroitin ABC
lyase (E.C. 4.2.2.4), which cleaves chondroitin and dermatan
sulfates  and  has  some  activity  against  hyaluronan;  and
Heparinase  III  (E.C.  4.2.2.8)  which  selectively  cleaves
heparan sulfates. All enzyme solutions were made fresh on
the  day  of  injection  by  dissolving  the  enzymes  in  sterile
phosphate-buffered saline (PBS).
Intravitreal injections: Prior to intravitreal injections, mice
were  anaesthetized  with  isoflurane.  One  drop  of  1%
proxymethocaine was applied topically to each eye as a local
anesthesia. A fine glass micropipette connected to a 5  μl
Hamilton glass syringe was passed at the equator through the
sclera and into the vitreous cavity, carefully avoiding the lens.
Each eye received two injections with a combined volume of
0.5  μl.  The  injections  were  administered  slowly  over
approximately  one  minute.  The  first  injection,  containing
0.25 μl of 1×1012 genomic particles/ml of AAV-2.CBA.eGFP
diluted at a ratio 1:5 with PBS (i.e., 5×107 genomic particles),
was followed immediately by a second 0.25 μl injection of
PBS containing either zero or varying amounts of enzyme.
Post procedure buprenorphine (0.1 mg/kg) was administered
subcutaneously for analgesia.
Electroretinography: Retinal function was evaluated 2 weeks
after intravitreal injection of 800 or 1,600 units of chondroitin
ABC lyase or heparinase III in 6 mice. Both dark- and light-
adapted electroretinograms (ERGs) were recorded. Briefly,
mice were dark adapted overnight and anesthetized with an
intraperitoneal injection of a mixture of ketamine (75 mg/ml,
10%) and xylazine (13.6 mg/ml, 20%). The mice were placed
on  a  heating  pad  during  the  procedure  to  maintain  body
temperature. Pupils were dilated with 1% tropicamide. A gold
wire loop electrode was placed on the surface of the cornea.
A  reference  electrode  was  inserted  into  the  left  cheek,  a
differential  electrode  was  placed  under  the  skin  on  the
forehead, and a neutral electrode was inserted subcutaneously
near  the  tail.  Electrical  signals  were  amplified  using  an
amplifier with 104× gain and a bandwidth of 0.1 to 1 kHz (–
3 dB points). Signals were digitized at a rate of 5.12 kHz. ERG
signals were averaged three to six times to reduce noise.
Retina flatmounts: Two weeks after injection, the mice were
euthanized and their eyes were then enucleated and fixed with
4% paraformaldehyde (PFA) for 1 h at room temperature. The
lenses were removed anteriorly under a light microscope. The
aphakic eyes were immersion-fixed in 4% PFA overnight at
4 °C and then washed with PBS. The entire retinas were
carefully dissected from the eyecup under a light microscope,
blocked with PBS containing 0.5% Triton X-100 for 1 h, and
were washed again with PBS buffer. To make flatmounts, the
retinas were mounted on glass slides, making four radial cuts
from  the  edges  to  the  equator  of  the  retina.  A  drop  of
Vectashield (Vector Laboratories Ltd., Peterborough, UK),
containing DAPI stain, was applied before coverslips were put
in place.
Cryosections: Two weeks post intravitreal injection, the mice
were euthanized and their eyes were enucleated. The cornea
and lens were removed anteriorly under a light microscope
and tissue was fixed with 4% paraformaldehyde (PFA) for 2–
3 h at room temperature. The eyecups were then washed in
PBS and immersion-fixed overnight in 30% sucrose in PBS.
Eyes were then embedded and frozen in an optimal-cutting
temperature  medium  (Raymond  A  Lamb  Ltd.,
Eastbourne,UK).  A  cryostat  was  used  to  obtain  5–10  µm
sections. These sections were mounted on a glass slide and a
drop of Vectashield (Vector Laboratories Ltd., Peterborough,
UK) containing DAPI stain was applied before coverslips
were put in place.
Microscopy: Flatmounts were examined using a Leica SP5
inverted  confocal  laser  scanning  microscope  (Argon  405
20%) with a 63× oil-immersion objective. To quantify GFP
expression, serial optical z-sectioning was performed over an
area of 0.056 mm2 on retina flatmounts and through the full
thickness of the retina. All images were taken under identical
conditions of laser intensity, brightness, and contrast. For
analyses of total fluorescence within a given portion of retina
the captured stacks of images were collapsed over the z-axis
Molecular Vision 2011; 17:1771-1783 <http://www.molvis.org/molvis/v17/a194> © 2011 Molecular Vision
1772into confocal projections using Leica Microsystems LAS AF
software. These z-sectioned constructs were then processed
using ImageJ Software (downloaded from National Institutes
of Health website).
Briefly, GFP fluorescence intensity was quantified in
pixels per area for each section in a confocal stack. The total
intensity was then summed for each stack. Low level, diffuse,
endogenous background fluorescence was variably present in
the  sections  in  the  confocal  stacks,  which  had  a  distinct
appearance  from  the  fluorescence  observed  in  GFP
transduced cells. Therefore, the threshold was adjusted for
each  z-construct  to  exclude  this  non-specific  background
fluorescence. To ensure equal starting plane depths, the retinal
tissue surface (vitreal side) was first focused by using plain
field light microscopy, and by then switching to the confocal
laser channels. For initial assessments of enzyme activity, four
randomly chosen sites in the mid-periphery of the retinal
flatmounts were analyzed (Figure 1A); for enzyme dose–
response curves, ten evenly spaced samples in a straight line
across the retina, which were centered upon but avoided the
optic nerve head, were analyzed (Figure 1B).
Retinal cryosections were analyzed under an Olympus
BX51 upright microscope using a 20×/0.30 Plan Fln objective
and captured using a Coolsnap ES camera (Photometrics,
Tucson, AZ) through MetaVue Software (Molecular Devices
Ltd. Wokingham, UK). Specific band pass filter sets for Texas
Red (to identify endogenous fluorescence), DAPI (to analyze
nuclei), and FITC (to analyze GFP expression), were used to
prevent bleed through from one channel to the next. Images
were then processed and analyzed using ImageJ.
Statistical analysis: Twelve eyes were injected for the initial
evaluation  of  each  enzyme  (three  eyes  per  enzyme
concentration) and four random retinal areas per eye were
analyzed  by  measuring  total  fluorescence  in  collapsed  z-
stacks. Geometric mean fluorescence intensity with a 95% CI
was  calculated  for  each  enzyme  concentration.  Data  are
presented as the percentage GFP intensity of the specified
enzyme concentrations compared with the control group (0
units  -  i.e.,  AAV-2.CBA.eGFP  with  no  added  enzyme).
Differences between groups were evaluated using one-way
ANOVA followed by Dunnett’s post-test in GraphPad Prism.
Significance was set at p<0.05.
For  enzyme  dose–response  curves  (chondroitin  ABC
lyase and heparinase III), three eyes were injected per enzyme
concentration and 10 retinal areas per eye were examined as
described above (Figure 1B). The geometric mean (geomean)
of these repeated measures was then calculated for each eye
to  estimate  the  fluorescence  for  subsequent  analysis  and
presentation.
RESULTS
Glycosidic  enzymes  enhance  retinal  transduction:
Collagenase, hyaluronan lyase, chondroitin ABC lyase, and
heparinase III were coinjected with AAV2.CBA.eGFP and
retinal fluorescence was analyzed using confocal microscopy.
As expected, the low dose of the AAV2 used (5×107 viral
particles) produced patchy, low intensity fluorescence in the
retina, which is indicative of limited GFP expression (Figure
2).  Collagenase  treatment  resulted  in  decreased  GFP
expression compared to AAV2 alone (Figure 2A). All of the
other enzymes tested drove an increase in GFP expression
Figure 1. Schematic representation of
the methodology used to quantify GFP
expression in mouse retina flatmounts.
Confocal  z-sectioning  (serial  optical
sections)  was  performed  in  areas  of
238×238 μm at 1 μm intervals through
the depth of the retina. All images were
captured under identical conditions of
laser intensity, brightness and contrast.
Slice image stacks were collapsed over
the  z-axis  into  confocal  projections
using  Leica  Microsystems  LAS  AF
software  and  processed  with  ImageJ
software  to  measure  the  total  (GFP
mediated)  fluorescence  in  pixels  per
area through the retinal depth. For initial
analyses of enzymes efficacy, an area
was  selected  at  random  in  the  mid-
periphery of each quadrant (A), and for
dose–response  curves  ten  areas  were
selected  along  a  randomly  chosen
straight extension across the retina (B).
All analyses were conducted blind to the
amount of enzyme used.
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1773(Figure 2A). The least effective was hyaluronan lyase, which
nonetheless  resulted  in  a  20-fold  increase  in  retinal
fluorescence at a dose of 100 units compared to the virus alone
and extended the fluorescence signal to cells deeper in the
retina  and  with  more  diverse  morphology.  The  two  other
glycosidic enzymes, chondroitin ABC lyase and heparinase
III,  produced  an  even  greater  enhancement  in  retinal
transduction. Chondroitin ABC lyase resulted in a 40 fold
increase in fluorescence at 50 units, a 65 fold increase at 100
units,  and  a  150  fold  increase  at  200  units.  Similarly,
heparinase III treatment at 50 units resulted in approximately
a 20 fold increase in AAV2 transduction, with a 50 fold
increase at 100 units, and a 150 fold increase at 200 units. The
chondroitin ABC lyase and heparinase III treatments (Figure
2B,C) resulted in a considerable increase in both the numbers
and  types  of  fluorescent  cells  compared  to  AAV2  alone
(retinal images presented are collapsed over the z-axis).
Enzyme  dose–response  curves:  Next,  a  wider  range  of
chondroitin ABC lyase and heparinase III concentrations was
investigated to establish an optimal dose for each enzyme.
Injections of six different concentrations were performed for
each enzyme: 0 units (the PBS control), 100, 200, 400, 800,
and 1,600 units. We quantified fluorescence intensity in ten
samples  per  eye  taken  in  a  line  across  the  width  of  the
flatmounts to account for possible regional variations in cell
transduction between central and peripheral retina (Figure
1B). Similar dose–response curves were observed for both
enzymes that plateaued between 200 and 400 units and had an
ED50 of between 100 and 200 units (Figure 3).
Transduction is observed across the retinal depth: The use of
glycosidic  enzymes  also  increased  the  depth  of  retinal
transduction. Images of confocal slices from the inner, central,
and outer retina following coinjection with heparinase III or
chondroitin ABC lyase that demonstrate the different types of
retinal  cells  transduced  are  shown  in  Figure  4.  Marked
fluorescence  was  seen  in  cell  bodies  and  structures  that
resembled nerve fibers proximal to the vitreous. Deeper in the
retina, fluorescence was observed in cells, including large
arborizing neurons. Finally, patchy fluorescence was seen in
the outer retina that co-localized with densely packed cell
nuclei  (observed  by  DAPI  stain),  suggesting  that  this
fluorescence was within photoreceptor cell bodies.
To confirm the GFP expression in different retinal layers
and  to  determine  the  retinal  cell  types  transduced  by  the
vector, we analyzed the fluorescence in histological cross
sections of the retina. We co-injected mice with AA2-GFP
and either 200 units of chondroitin ABC lyase (n=4 eyes) or
heparinase III (n=4). The controls were injected with AAV2
and PBS (n=4). A double negative control with no injections
(n=2)  was  included  to  show  any  endogenous  retinal
florescence. Our results confirmed that the use of glycosidic
enzymes  increased  both  the  number  and  type  of  cells
transduced across the retinal layers. Exemplar cross section
images of the retina are shown in Figure 5, Figure 6, and
Figure 7. Figure 5A shows the endogenous autofluorescence
that  was  sometimes  present  in  the  layer  containing  the
photoreceptor outer segments; this was observed in both the
red and green channels, thereby distinguishing it from GFP
fluorescence, which was observed in the green channel only.
GFP expression was observed in occasional ganglion cells in
eyes only treated with AAV2 without enzymes (Figure 5B).
Co-injection  with  chondroitin  ABC  lyase  resulted  in
greatly enhanced GFP expression in the inner retina (Figure
6A) and there was some expression throughout the retinal
layers, including Müller cells (Figure 6B), INL cells (Figure
6C), and ONL photoreceptors (Figure 6D,E). However, the
pattern  of  transduction  was  patchy  in  most  injected  eyes.
Similarly, co-injection of 200 units of heparinase III also
produced a marked improvement in transduction across the
retina (Figure 7A-G). GFP expression was most prominent in
retinal ganglion cells (Figure 7A-E,G) and it was also detected
in Müller cells (Figure 7D,E), in INL cells (Figure 7A-G), and
in  photoreceptors  (Figure  7F,G).  All  histological  sections
appeared  morphologically  intact,  so  the  enzymes  did  not
produce an obvious disruption of retinal architecture.
Analysis of retinal function in the presence of enzymes: To test
the  effect  of  glycosidic  enzymes  on  retinal  function,  we
recorded ERGs after digestion with 800 or 1,600 units of
heparinase  III  and  chondroitin  ABC  lyase  (i.e.,  higher
concentrations  than  required  for  maximal  retinal
transduction).  ERGs  were  present  and  retained  all  major
components (a-wave, b-wave, and oscillatory potentials) in
mice treated with the AAV2.CBA.eGFP vector in conjunction
with either 800 or 1,600 units of heparinase III or 800 units of
chondroitin ABC lyase (Figure 8). However, a reduction in
ERG amplitude was seen after intravitreal injections of 1,600
units of chondroitin ABC lyase.
DISCUSSION
AAV-mediated gene therapy holds great promise for treating
or  preventing  visual  loss  in  retinal  dystrophies  and  other
retinal conditions. Recently, remarkable progress has been
made both in experimental approaches using animal models
and in moving this technology into clinical trials. However,
there is a need to improve transduction efficiency to broaden
the applicability of AAV-mediated retinal gene therapy. There
are several possible ways to improve AAV-mediated retinal
transduction. The viral titer can be increased, but levels may
be limited by the potential for immunogenicity [10]. Hybrid
AAV can be constructed using the genome of one serotype,
but using a packing capsid from another [1]. The AAV capsid
can  be  mutated  to  enhance  tropism  and  the  efficiency  of
transgene  expression;  for  example,  recent  experiments  in
which  surface  exposed  tyrosine  residues  are  mutated  to
decrease intracellular degradation show considerable promise
[5]. A further approach is to tackle the physical barriers that
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1774prevent the AAV passing into and through the retina and this
is the strategy explored in this study.
We hypothesized that after intravitreal injection, the viral
particles become trapped in the extracellular matrices and by
the cell surface proteoglycans found in the untreated vitreous,
ILM, and neurosensory retina. These layers can form both
physical and charge barriers that can limit the efficacy of
trans-retinal penetration of macromolecules. Each barrier has
a different GAG content and concentration and therefore leads
to a variable level of viral entrapment [11-13]. HA and CSPGs
in the vitreous; HA, CSPGs, and HSPGs in the ILM; and
CSPGs and HSPGs in the retinal matrix could all inhibit viral
Figure  2.  Retinal  fluorescence  two
weeks after the intravitreal delivery of
AAV2.CBA.eGFP  and  other  different
enzymes.  A:  Quantitative  analysis  of
fluorescence following treatment with
the AAV2 and collagenase, hyaluronan
lyase,  chondroitin  ABC  lyase,  or
heparinase  III  in  increasing
concentrations. Data are geomeans with
a ±95% CI (n=9 eyes), and show the
percentage  fluorescence  intensity
relative to that induced by AAV2 alone
(0  unit  control  group,  n=3  eyes).  B:
Confocal  projection  of  optical  z-
sections  demonstrating  fluorescence
after co-injection with chondroitin ABC
lyase at the dose indicated. C: Confocal
projection  of  optical  z-sections
demonstrating  fluorescence  after  co-
injection with heparinase III at the dose
indicated.
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1775transduction. However, electrostatic binding to the negatively
charged GAGs is unlikely to impede vector penetration of the
tissue because at a physiologic pH of 7.35, AAV with an
isoelectric point ranging between 5 and 7 (depending on the
serotype), would have an overall negative charge and would
repel the anionic GAGs [14,15].
The major impedance is therefore likely to be due to the
diffusion  barrier  caused  by  the  vitreal,  ILM,  and  retinal
matrices (i.e., interphotoreceptor matrix), the external limiting
membrane (ELM), and cell surface proteoglycans [16-18].
Possibly the most important barrier for these matrices is the
inner  limiting  lamina  (ILL),  the  basement  membrane  of
Müller cells, which has pore channels varying in size from 10
to 25 nm (in rabbit retina) [17], whereas the AAV viral capsid
has a total radius between 20 and 25 nm [19]. The intraocular
movement of larger particles was investigated by Kamei et al.
[18] who demonstrated that an intravitreally injected 70 kDa
tissue plasminogen activator could not diffuse across the ILM
in  rabbits.  Another  study  of  antibodies  delivered  into  the
vitreous cavity of rhesus monkey found that Fab antibodies
(48 kDa) diffused across the retina, but full-length antibodies
(148 kDa) did not [20]. A further in vitro study by Jackson et
al. [21] looked at the maximum size of the molecules capable
of  freely  diffusing  across  human  retina,  or  the  retinal
exclusion  limit  (REL),  using  FITC-dextrans  of  various
molecular weights. They found the REL in human neuroretina
to  be  76.5±1.5  kDa  (6.11±0.04  nm).  Furthermore,  they
observed  only  moderate  interspecies  variations  in  animal
studies  including  those  that  for  pigs,  cattle,  and  rabbits
(60±11.5, 78.5±20.5, and 86±30 kDa, respectively), which are
commonly used to model human disease. Interestingly, they
found that in human retina, the inner and outer plexiform
layers  formed  the  sites  of  highest  resistance  to  diffusion,
which were even greater than the ILM. Larger molecules were
capable of crossing the retina, although the rate of diffusion
was much reduced.
The wild-type murine retinas show very limited inner
retinal penetration by intravitreally delivered AAV vectors.
This lack of permeability into the outer retina is not dependent
on AAV serotype including types 2, 5, 7, 8, and 9 as shown
in a study by Lebherz et al. [22]. The researchers showed that
after intravitreal injection into mouse eyes, only AAV2 and
AAV8  were  able  to  transduce  retinal  ganglion  cells  and
AAV2, 8, and 9 transduced occasional Müller cells. None of
the  other  vectors  tested  demonstrated  significant  retinal
expression  after  intravitreal  injection.  Interestingly,  viral
particles spread into the outer retina and RPE after intravitreal
delivery in degenerate retinas compared to their accumulation
at the ILM in normal rat retina [23]. Immunohistochemistry
showed changes in the architecture of the ILM, which are
likely to underlie the increased viral transduction in diseased
tissue.  Similarly,  the  lack  of  retinoschisin  (Rs1)  causes  a
marked  change  in  the  permeability  of  the  retina  to  AAV
vectors,  as  serotypes  including  2,  5,  and  8  were  able  to
penetrate  all  retinal  layers  of  Rs1-KO  mice  and  even  to
transduce the retinal pigment epithelium from the vitreous
[24].
Previous  studies  have  investigated  the  disruption  of
extracellular barriers in ocular gene therapy. Gruter et al.
[25] investigated the effects of enzymatic digestion on the
barrier  properties  of  the  interphotoreceptor  matrix  (IPM)
following subretinal injections of lentiviral vector aimed at
transfecting  photoreceptors.  Digestion  of  the  IPM  with
neuraminidase X, and to a lesser extent with chondroitinase
ABC  (digesting  mainly  cone  matrix),  resulted  in  some
improvement  in  photoreceptor  transduction.  A  recent
Figure  3.  Dose–response  curves
showing treatment with A: Chondroitin
ABC  lyase,  and  B:  Heparinase  III.
Values  for  fluorescence  intensity
represent the mean±SD (n=3 eyes). For
both enzymes, the ED50 was between
100 and 200 units.
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1776Figure 4. Sample confocal slices of retinas treated with AAV2.CBA.eGFP and heparinase III or chondroitin ABC lyase. GFP fluorescence
and DAPI staining are merged and the images correspond to A and D: the inner retina, B and E: the mid retina, and C and F: the outer retina.
Image sizes 238×238 µm.
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1777publication by Dalkara et al. [26] demonstrated that AAV2
localized  at  the  ILM  after  intravitreal  injection  and  that
digestion of the ILM with pronase E, a nonspecific protease,
qualitatively improved retinal transduction. It has also been
shown  that  degradation  of  intra-retinal  GAGs  with
chondroitin  ABC  lyase  promotes  the  migration  and
integration  of  stem  cells  into  degenerating  retina  [27].
Consistent with other publications [1,26] we observed that
Figure  5.  Representative  cross-sectional  micrographs  show  both  untreated  retinas  and  retinas  two  weeks  after  transduction  with
AAV2.CBA.eGFP, but with no enzyme treatment. A: Some sections of retina with no treatment (control) showed patchy autofluorescence in
the photoreceptor outer segment layer. This could be distinguished from GFP fluorescence because it was observed in both red and green
channels (see also Figure 6A, Figure 7D,E). B: Retina treated with AAV2.CBA.eGFP vector showed low transduction of the GCL. Texas
Red filter is shown in the left panel; FITC filter is shown in the center panel; DAPI filter is shown in the right panel. Calibration bar 50 μm.
Ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), Outer nuclear layer (ONL),
Outer segments (OS) and Retinal pigment epithelium (RPE). Green arrow shows a retinal ganglion cell.
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1778Figure 6. Representative cross sectional micrographs showing various retinal cell types transduced by AAV2.CBA.eGFP after treatment with
chondroitin ABC lyase. A-E: A wide range of cell types were transduced in retinas treated with AAV2.CBA.eGFP vector and 200 units of
chondroitin ABC lyase. GFP fluorescence was observed across the retinal layers, including cells with the anatomic location and morphology
of; A: ganglion cells, B: Müller cells, C: INL cells, and D, E: photoreceptors. FITC filter is shown in the left panel; DAPI filter is shown in
the right panel. Calibration bar 50 µm. Ganglion cell layer (GCL), inner nuclear layer (INL), outer nuclear layer (ONL), outer segments (OS).
Green arrow shows a retinal ganglion cell. Blue arrow shows a Müller cell. Orange arrow shows cells in inner nuclear layer. Red arrow shows
a photoreceptor cell.
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1779intravitreally delivered AAV2 alone leads to a low retinal
transduction  rate.  Collagenase  digestion  decreased  retinal
transduction  efficiency,  but  chondroitin  ABC  lyase,
heparinase  III  and,  to  a  lesser  extent,  hyaluronan  lyase
Figure 7. Representative cross sectional micrographs showing various retinal cell types transduced by AAV2.CBA.eGFP after treatment with
heparinase III. A-G: After two weeks retinas treated with AAV2.CBA.eGFP vector and 200 units of heparinase III showed GFP expression
across all retinal layers including cells with the anatomic location and morphology of (A-E, G) ganglion cells, (A-G) INL cells, (D, E) Müller
cells, and (F, G) photoreceptor cells. FITC filter is shown in the left panel; DAPI filter is shown in the right panel. Calibration bar 50 µm.
Ganglion cell layer (GCL), inner nuclear layer (INL), outer nuclear layer (ONL), outer segments (OS). Green arrow shows a retinal ganglion
cell. Blue arrow shows a Müller cell. Orange arrow shows a cell in inner nuclear layer. Red arrow shows a photoreceptor cell.
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1780increased expression of the viral reporter gene. It is likely that
the  glycosidic  enzymes  promote  viral  transduction  by
breaking down vitreal and retinal extracellular matrices, thus
increasing the size of the matrix pores and allowing AAV to
move across these barriers with more ease.
The differences observed in the effects of these glycosidic
enzymes might be explained by regional variations in GAG
content and concentration. The highest concentration of HA
is in the vitreous. However, as the vitreous contains such a
dilute  extracellular  matrix,  it  may  not  greatly  impede  the
movement of AAV particles, so digestion of the vitreous HA
Figure  8.  Electroretinograms  (ERGs)
following  intravitreal  delivery  of
AAV2.CBA.eGFP  vector  and
heparinase  III  or  chondroitin  ABC
lyase.  A:  Dark-adapted  ERGs  were
intact  following  enzyme  injection  of
heparinase  III  at  800  units.  B:  Dark-
adapted  ERGs  were  intact  following
enzyme  injection  of  heparinase  III  at
1,600  units.  C:  Dark-adapted  ERGs
were intact following enzyme injection
of chondroitin ABC lyase at 800 units.
D: A higher dose of chondroitin ABC
lyase  (1,600  units)  impaired  retinal
function.  Records  show  average
responses  to  repeated  flash
presentations  in  individual  mice.
Timing of each flash is indicated by the
arrow,  with  flash  intensity  (in  log10
μW.cm−2) shown to the left of each ERG
trace.
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1781network with hyaluronan lyase may have a modest effect, as
observed in our study. The ILM has been shown to be a barrier
to AAV entering the retina [26] and a major barrier within this
structure  is  likely  to  be  the  ILL,  where  the  predominant
proteoglycans  are  thought  to  be  heparan  sulfate
proteoglycans.
Therefore, the major effect of heparinase III digestion is
likely to be an increase in permeability of the ILL. However,
a  recent  study  by  other  researchers  in  our  laboratory  has
demonstrated that ILM also contains chondroitin sulfate (CS)
and dermatan sulfate (DS) GAGs (unpublished observation).
This could explain the equally robust effect of chondroitin
ABC lyase in increasing retinal transduction by its action on
the ILL. Furthermore, both CSPGs and HSPGs are abundant
in the other retinal layers, including the nerve fiber layer, the
inner and outer plexiform layers, and in the interphotoreceptor
matrix.  Hence,  digestion  with  chondroitin  ABC  lyase  or
heparinase III could make any of these retinal layers more
porous and thus improve the trans-retinal penetration of the
viral vector.
It is of interest to note that heparinase III was effective at
increasing retinal transduction, as infection of cells by AAV2
has  been  shown  to  be  heparan  sulfate  dependent  [28].
However, cell surface heparan sulfate proteoglycans are not
always required for internalization of AAV2 [28,29], so their
removal  by  heparinase  III  digestion  may  not  have
compromised the ability of retinal cells to take up the AAV2.
Alternative  explanations  are  that  the  digestion  of  retinal
heparan sulfates was incomplete, or that new cell surface
heparan sulfate proteoglycans were synthesized, permitting
AAV2  entry  into  the  retinal  cells  after  the  heparinase  III
digestion (which is likely to have a short duration of action)
had disrupted extracellular barriers, facilitating movement of
the virus particles into and within the retina.
The use of intravitreally-delivered glycosidic enzymes
for other purposes has been investigated. Hyaluronidases and
chondroitinase  have  been  tested  in  animal  models  for
pharmacological  vitreolysis  without  any  reported  adverse
effects  [30-32].  Furthermore,  highly  purified  ovine
hyaluronidase  VitraseTM  (ISTA  Pharmaceuticals,  Irvine,
CA) has been used in clinical trials to aid the dispersion of
vitreous  hemorrhage  [33].  We  investigated  whether  the
enzymes had functional effects on the retina, by measuring
ERGs, and found that light responses appeared intact after
digestion with 800 units of heparinase III or chondroitin ABC
lyase i.e., at a dose that was considerably higher than the 200
units  required  for  maximal  retinal  transduction.  It  is  still
possible that these enzymes damage inner retinal function at
doses of 800 units or less, but it is of note that in experiments
with  pronase  E,  measuring  ERGs  was  a  more  sensitive
indicator  of  retinal  damage  than  measuring  VEPs  [26].
Nevertheless, an important element of future work will be to
focus on the more extensive assessment of any acute and/or
chronic effects these glycosidic enzymes may have on retinal
function.
Taken together, our data suggest that heparinase III or
chondroitin ABC lyase greatly increased retinal transduction
by  intravitreal  AAV2.  This  approach  will  be  useful  for
experimental gene transfer into the retina using rodent models
and may broaden the applicability of AAV-mediated gene
therapy for treating human disease.
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